Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its ...

coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the ...

R&D Expenses: Research and development expenses for the year ended December 31, 2024 decreased to approximately $2,044,000 ...

McGill University researchers have demonstrated that AMPA receptors (AMPARs), which mediate fast excitatory neurotransmission ...

Protalix Biotherapeutics (PLX) has gained investor’s attention, and reported a record revenue increase in its fiscal year 2024, primarily due ...

India’s Aditya-L1 captures an unprecedented solar flare, IISc researchers unlock gene activation with mini proteins in yeast, ...

Transfect the cells with the recombinant vector using Lipofectamine ... Use the cells on the coverslip to check the level of GFP fusion protein expression with high-resolution fluorescence ...

Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to acceler ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

The Central Board of Secondary Education (CBSE) is conducting the Class 12 board exams for the 2025 academic year. The ...

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: ...